A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

Chronic Hepatitis B and Hepatitis D Co-infection Clinical Trial

Official title: An Open-label Phase IIa Study to Evaluate the Antiviral Effect and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and D Co-infection

Status Terminated

Clinical Trial Summary

This is an open-label phase IIa study of HH-003 to evaluate its antiviral activity and safety in subjects with chronic hepatitis B and hepatitis D co-infection. HH-003 is a human monoclonal antibody targeting the pre-S1 domain of the HBV large envelope protein. It blocks engagement of preS1 with sodium taurocholate co-transporting polypeptide (NTCP), the cellular receptor for HBV/HDV.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Coinfection
• Communicable Diseases
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis D
• Hepatitis, Chronic
• Infections

• NCT number: NCT05674448
• Study type: Interventional
• Source: Huahui Health
• Status: Terminated
• Phase: Phase 2
• Start date: August 11, 2021
• Completion date: January 4, 2023